dacarbazine and trimetrexate
dacarbazine has been researched along with trimetrexate in 4 studies
Research
Studies (4)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Dasgupta, A; Shields, JE; Spencer, HT | 1 |
Reviews
1 review(s) available for dacarbazine and trimetrexate
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
3 other study(ies) available for dacarbazine and trimetrexate
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Coculture Techniques; Combined Modality Therapy; Cytotoxicity, Immunologic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Genetic Engineering; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Mice; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; NK Cell Lectin-Like Receptor Subfamily K; Recombinant Proteins; Temozolomide; Tetrahydrofolate Dehydrogenase; Trimetrexate; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |